<DOC>
	<DOCNO>NCT00684866</DOCNO>
	<brief_summary>The purpose study compare safety tolerability levalbuterol HFA meter dose inhaler ( MDI ) versus racemic albuterol HFA MDI pediatric subject 4-11 year age asthma</brief_summary>
	<brief_title>Safety Tolerability Study Levalbuterol HFA Racemic Albuterol HFA Pediatrics Subjects With Asthma</brief_title>
	<detailed_description>A randomized , double-blind , active-controlled multicenter , two-way crossover study HFA levalbuterol ( without spacer ) subject 4-11 year age asthma . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Subject , male female , must age 4 11 year , inclusive , time consent . Female subject 8 year age older negative serum pregnancy test study start . Subject must document diagnosis asthma minimum 6 month prior study start . Subject must good health exception reversible airway disease suffer chronic condition might affect respiratory function . Subject must chest Xray one take within 12 month prior randomization may use . Subject 's parent/legal guardian must able complete diary card medical event calendar reliably daily basis understand dose instruction . Any subject able must parent/legal guardian assist study activity . Female subject pregnant lactating . Subject participate investigational drug study within 30 day prior study start , currently participate another clinical trial . Subject whose schedule prevents take first daily dose study medication and/or start study visit 9 AM . Subject travel commitment study would interfere trial measurement compliance . Subject history hospitalization asthma within 4 week prior study start , schedule inpatient hospitalization , include elective surgery course trial Subject know sensitivity levalbuterol racemic albuterol , excipients contain formulation . Subject use prescription drug albuterol sulfate administration contraindicate . Subject currently diagnose lifethreatening asthma define history asthma episodes require intubation , associate hypercapnia , respiratory arrest , hypoxic seizure within 3 month prior study start . Subject history cancer . Subject hyperthyroidism , diabetes , hypertension , cardiac disease seizure disorder . Subject history substance abuse drug abuse within 12 month precede study start . Subject history cigarette smoking use tobacco product . Subject documented history bronchopulmonary aspergillosis form allergic alveolitis . Subject suffer clinically significant upper low respiratory tract infection 2 week prior study start . Subject unstable asthma ; change asthma therapy ; visit Emergency Department hospital worsen asthma within 4 week . Subject staff member relative staff member .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Levalbuterol</keyword>
	<keyword>Racemic Albuterol</keyword>
</DOC>